ENCOURAGING SIGNS IN UK TECHNOLOGY MARKETS
08 March 2004 - Cambridge Consultants

This week sees the second successful flotation on the UK hi-tech market in as many weeks. Ark Therapeutics Group plc is the first biotech company to list on the London Stock Exchange for a number of years. Cambridge Consultants Ltd's IPO team wrote the independent Expert's Report which formed part of Ark's listing prospectus addressing the merits of Ark's products, aspects of its business plan and associated risks.

Ark is an emerging healthcare company with a product already in hospitals for the treatment of leg ulcers (Kerraboot), with three further lead products including novel gene-based therapies, in late stage clinical development. The company has a complex portfolio of both product and device, an unusual mix for today's healthcare companies, and focuses on specialist medicines in areas where there are high unmet clinical needs. CCL's team therefore needed to cover medical devices for woundcare through to the application of gene therapy in oncology.

Ark's listing follows hot on the heels of Cambridge Silicon Radio which floated last week, a spin-off of CCL.

'Glimmers of hope are finally appearing in the European technology market following Ark's announcement,' said Dr Monika Green, leader of CCL's healthcare consulting arm. 'We have seen a rise in confidence across the technology sector, and now we are seeing it in Biotech which has been particularly subdued over the last couple of years,' she continued.

http://www.cambridgeconsultants.com/

More News:
  • For March 2004
  • From Cambridge Consultants
  • For Medical Equipment